

સચિન GIDC ખાતે ડિવાઈડર ઓળંગતી વેળા વાહન અડફેટે યુવકનું મોત

સુરત, તા.૨૦

સચિન જીઆઈડીસી ખાતે ડિવાઈડર ક્રૂદીને રસ્તો ઓળંગતો યુવક વાહન અડફેટે ચડતા તેનું મોત નિપજ્યું હતું.

મૂળ મહારાષ્ટ્ર જલગાંવનો વતની અને હાલ સચિન જીઆઈડીસી વિસ્તારમાં આવેલ જલારામનગરમાં આવેલી કંપનીમાં રહેતો સંદીપ ચરણદાસ ભગત (32 વર્ષ) પત્ની સાથે રહી ત્યાંજ નોકરી કરતો હતો. ગઈ કાલે સાંજે સંદીપ ઘરેથી સામાન લેવા બહાર નિકળ્યો હતો. સંદીપ સામાન લઈને ઘરે પરત આવી રહ્યો હતો. તે દરમિયાન સચિન જીઆઈડીસી રોડ નંબર 5 S.P એન્જિનિયર નામની કંપની પાસે સંદીપ ડિવાઈડર ક્રૂદીને રોડ ઓળંગી રહ્યો હતો. ત્યારે કોઈ અજાણ્યા વાહન ચાલકે ગફલતભરી રીતે હંકારી સંદીપને અડફેટે લીધો હતો. જેથી સંદીપનું ઘટનાસ્થળે જ મોત નિપજ્યું હતું. બનાવને પગલે સચિન જીઆઈડીસી પોલીસના સબ ઇન્સ્પેક્ટર ડી.કે સોલંકી વધુ તપાસ કરી રહ્યા છે.

વેડરોડ પર દોડતી મનપાની સીટી બસમાં બેટરી ફાટતા આગ

સુરત, તા.૨૦

વેડરોડની અંખડઆંનદ કોલેજ પાસેથી પસાર થઈ રહેલી મનપાની સીટીબસની બેટરીમાં આગ ફાટી નિકળતા ભાગદોડ મચી જવા પામી હતી. ઘટનાની જાણ થતા કતારગામ ફાયર સ્ટેશનના લાશકરો સ્થળ પર દોડી આવ્યા હતા. અને આગ ઓલવી કાઢી હતી.

ફાયર બ્રિગેડના સુત્રો પાસેથી મળતી માહિતી અનુસાર આજે બપોરના ૧૨.૩૦ વાગ્યાના અરસામાં વેડરોડ પરની અખડઆંનદ કોલેજ પાસેથી મનપાની સીટી બસ (જીજે ૦૫ બીજે ૦૭૫૧) પસાર થઈ રહી હતી. દરમિયાન બસની બેટરીમાં આગ ફાટી નિકળતા ભાગદોડ મચી જવા પામી હતી. બસના મુસાફરોએ બુમાબુમ કરી દેતા ડ્રાઈવરે બસ સાઈડ પર પાર્ક કરીને તમામ મુસાફરોને ઉતારી દીધા હતા. ઘટનાની જાણ થતા કતારગામ ફાયર સ્ટેશનના લાશકો સ્થળ પર દોડી આવ્યા હતા. અને સતત પાણીનો મારો ચલાવી ગણતરીની મિનિટમાં આગ ઓલવી કાઢી હતી. સદનસીબે આ ઘટનામાં કોઈને ઇજા કે કોઈ જાનહાની નહી થતા મોટી હોનારત થતા અટકી હતી.

ઈચ્છાપોરનાં ગવીયર ગામ પાસેથી ૧૫ હજાર લીટરથી વધુ બાયોડિઝલનો જથ્થો ઝડપાયા

સુરત, તા.૨૦

ઈચ્છાપોર ગવીયર ગામ મહાકાળીના મંદીર પાસેથી સ્ટેટ મોનીટરીંગ સેલે ૧૫ હજાર લીટરથી વધુ બાયોડિઝલનો જથ્થો ઝડપી પાડી એક આરોપીની ધરપકડ કરી ત્રણ જણાને વોન્ટેડ જાહેર કર્યા હતા. આ મામલે સ્ટેટ મોનીટરીંગ સેલ દ્વારા ઈચ્છાપોર પોલીસ મથકમાં ગુનો નોંધાવવામાં આવ્યો હતો.

પ્રાપ્ત વિગતો અનુસાર સ્ટેટ મોનીટરીંગ સેલની ટીમે ઈચ્છાપોર ગવીયર ગામ મહાકાળીના મંદીર પાસેથી ગવીયર ગામના ઓરા કળીયામાં રહેતા તેજશ લાલજી પટેલને ૧૫,૨૦૦ લીટર બાયોડિઝલ (કિંમત રૂ.૬.૮ લાખ) સાથે ઝડપી કર્યો હતો. પોલીસે બાયોડિઝલ સહીત કુલ રૂ.૮.૬૩ લાખની માત્રા કબ્જે કરી હતી. પકડાયેલા તેજશ લાલજી પટેલની પુછપરછમાં તેણે રાજેશ મોહનભાઈ પટેલ તથા મનીષ બાબુભાઈ પટેલ (રહે. ગવીયર ગામ, ડુમસ રોડ) પાસેથી આ ડીઝલનો જથ્થો લીધો હોવાનું કબુલ્યું હતું. સ્ટેટ મોનીટરીંગ સેલ દ્વારા ઉપરોક્ત બંને આરોપી ઉપરાંત ધનેશ પટેલ (રહે. વેસુગામ) ને વોન્ટેડ જાહેર કરાયા હતા.

ભરૂચના ઉમલ્લા પોલીસે વિદેશી દારૂ સાથે એકને ઝડપી પાડ્યો

અધિયા: અધિયાના ઉમલ્લા પોલીસે ભાતમીના આધારે તવડી ગામની કનાલ પાસે મોટર સાયકલ સવાર વિકાસ વસાવાને દારૂ સાથે ઝડપી પાડ્યો હતો. જ્યારે બાઈક પર પાછળ બેસેલો રાજ વસાવા અંધારાનો લાભ લઈ નાસી છુટ્યો હતો. પોલીસે વિકાસ વસાવા વિદેશી દારૂની ૧૪૪ નંગ બોટલો કબજે કરી હતી. ઉમલ્લા પોલીસે વિકાસ મહેશ વસાવા, રાજ ભટત વસાવા બંને રહે. પ્રતાપનગર તા. નાંદોદ જી. નર્મદા વિરુદ્ધ ફરિયાદ નોંધી કાર્યવાહી હાથ ધરી હતી.

(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)



MAITREYA MEDICARE LIMITED

Our Company was originally incorporated as 'Maitreya Medicare Private Limited' a private limited company under the Companies Act, 2013 at Surat Gujarat, pursuant to a certificate of incorporation dated March 28, 2019, issued by the Registrar of Companies, Central Registration Centre (CRC) ("RoC"). Thereafter, name of our Company was changed from 'Maitreya Medicare Private Limited' to 'Maitreya Medicare Limited', consequent to conversion of our Company from private to public company, pursuant to a special resolution passed by the shareholders of our Company on March 06, 2023, and a fresh certificate of incorporation consequent to change of name was issued by the RoC on March 30, 2023. Our Company's Corporate Identity Number is U24290GJ2019PLC107298. For details of change in Registered office of our Company, please refer to the chapter titled "History and Certain Corporate Matters" on page 166 of the Red Herring Prospectus dated October 19, 2023 filed with ROC.

Registered Office: Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat-395007 India. Tel: +91 98798 89506; Website: www.maitreyahospitals.com; Contact Person: Ms. Payal Mathur, Company Secretary and Compliance Officer; E-mail id: cs@maitreyamedicareltd.com Corporate Identity Number: U24290GJ2019PLC107298

OUR PROMOTERS: DR NARENDRA SINGH TANWAR, DR. PRANAV ROHITBHAI THAKER AND MR VIMALKUMAR NATVERLAL PATEL

THE ISSUE

INITIAL PUBLIC OFFER OF UP TO 18,16,000 EQUITY SHARES OF FACE VALUE ₹ 10 EACH (THE "EQUITY SHARES") OF MAITREYA MEDICARE LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ [●] PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING UP TO ₹ [●] THOUSANDS (THE "ISSUE") OF WHICH 1,08,800 EQUITY SHARES AGGREGATING TO ₹ [●] THOUSANDS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 17,07,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE AGGREGATING UPTO ₹ [●] THOUSANDS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE "PUBLIC ISSUE" AND THE "NET ISSUE" WILL CONSTITUTE 26.80 % AND 25.19 % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

The Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. This Issue is being made by our company in terms of Regulation of 229 (1) of SEBI ICDR Regulations read with Rule 19(2)(b)(i) of SCRR wherein not less than 25% of the post – issue paid up equity share capital of our company are being offered to the public for subscription. (For further details please see section titled "Issue Structure" beginning on page 311 of the Red Herring Prospectus). A copy of Red Herring Prospectus is delivered for filing to the Registrar of Companies as required under section 26(4) of the Companies Act, 2013.

QIB PORTION: NOT MORE THAN 50.00% OF THE NET ISSUE | NON-INSTITUTIONAL PORTION: NOT LESS THAN 15.00% OF THE NET ISSUE
RETAIL PORTION: NOT LESS THAN 35.00% OF THE NET ISSUE | MARKET MAKER PORTION: UPTO 17,07,200 EQUITY SHARES, [·]% OF THE ISSUE

PRICE BAND: ₹ 78 TO ₹ 82 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH

THE FLOOR PRICE IS 7.8 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 8.2 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

BIDS CAN BE MADE FOR A MINIMUM OF 1600 EQUITY SHARES AND IN MULTIPLES OF 1600 EQUITY SHARES

Risk to Investors:

1. We are highly dependent on our doctors, nurses and other healthcare professionals, as well as other key personnel and the loss of, or inability to attract or retain, such persons could adversely affect our business and results of operations.
2. The Merchant Banker associated with the issue has handled 16 public issues in the past two years out of which no issues closed below the Issue Price on Listing Date.
3. Average cost of acquisition of Equity Shares held by the Promoters Dr. Narendra Singh Tanwar, Mr. Vimalkumar Natverlal Patel and Dr. Pranav Rohitbhai Thaker is ₹ 2.40, ₹ 0.02 and ₹ 0.02 respectively per Equity Share and the Issue Price at the Upper end of the Price Band is ₹ 82 per Equity Share.
4. The Price /Earnings ratio based on the Diluted EPS for year ended Sept 2023 for the company at the upper end of the Price Band is ₹ 16.02.
5. Weighted Average Return on Net worth for Fiscals 2023, 2022 and 2021 is 45.99%.
6. We may generate revenue from the arrangements with government sponsored health schemes, any adverse change in these regulations/government policies related to such schemes may adversely affect our business, results of operations, cash flows and prospects.
7. We are yet to apply for approvals and licenses for our proposed Valsad hospital in our subsidiary company Maitreya Hospital Pvt Ltd and can be applied only after operations are commenced, so in case we are unable to obtain required applicable approvals and licenses on time it will effect the company's revenues, credibility and future plans.
8. Our operations are geographically located in one area at present and any localized social unrest, natural calamities, etc. could have material adverse effect on business and financial operations.

ISSUE PROGRAMME

ANCHOR INVESTOR BID/ ISSUE PERIOD*: OCTOBER 26, 2023*

BID/ ISSUE OPENS ON: OCTOBER 27, 2023 | BID/ ISSUE CLOSES ON: NOVEMBER 01, 2023

* The company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Issue Period shall be one Working Day prior to the Bid/ Issue opening Date.

THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ('NSE EMERGE')


In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.



The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50 % of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion", of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs (the "Net QIB Portion"). Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders ("Non-Institutional Portion") and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders ("Retail Portion") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism, if applicable, in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 315 of the Red Herring Prospectus. A copy of the Prospectus will be delivered for registration to the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

Bidders/Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/ Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/ Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an Issue. Bidders/ Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/ Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with AADHAR and are in compliance with CBDT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company see section titled "History and Certain Corporate Matters" on page 166 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section titled "Material Contracts and Documents for Inspection" on page 393 of the Red Herring Prospectus.

LIABILITY OF MEMBERS AS PER MOA: The liability of the members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.

ASBA *	Simple, Safe, Smart way of Application- Make use of it!!!		UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to ₹ 500,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. UPI Bidders also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and the subsequent press releases, including press release dated June 25, 2021 read with press release dated September 17, 2021.
*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details check section on ASBA.	ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by (i) Retail Individual Bidders in the Retail Portion; (ii) Non-Institutional Bidders with an application size of up to ₹ 5,00,000 in the Non-Institutional Portion and the (iii) Eligible Employees, under the Employee Reservation Portion. For details on the ASBA and UPI process, please refer to the details given in the Bid Cum Application Form and abridged prospectus and also please refer to the section "Issue Procedure" on page 315 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. The Bid Cum Application Form and the Abridged Prospectus can be downloaded from the website National Stock Exchange of India Limited ("NSE", and "Stock Exchange") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpFyes&intmlId=35 and https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpFyes&intmlId=43, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. HDFC Bank Limited has been appointed as the Sponsor Banks for the Issue, in accordance with the requirements of SEBI circular dated November 1, 2018 as amended. For UPI related queries, investors can contact NPCI at the toll-free number-18001201740 and Mail ID- ipo.upi@npci.org.in. For issue related grievance investors may contact: GYR Capital Advisors Private Limited - Mr. Mohit Baid (+91 877564648) (Email ID: info@gyrcapitaladvisors.com).		

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
 GYR Capital Advisors Private Limited 428, Gala Empire, Near JB Tower, Drive in Road, Thalteji, Ahmedabad-380 054, Gujarat, India. Telephone: +91 8777564648; E-mail id: info@gyrcapitaladvisors.com Website: www.gyrcapitaladvisors.com; Investor Grievance e-mailID: investors@gyrcapitaladvisors.com Contact Person: Mohit Baid; SEBIRegistrationNumber: INN000012810 CIN: U67200GJ2017PTCO96908	 Link Intime India Private Limited C-101, 1 st Floor, 247 Park, Lal Bhadur Shastri Marg, Vikhroli (West), Mumbai 400 083 Maharashtra, India Telephone: +91 810 811 4849; E-mail id: ipo@linkintime.co.in Website: www.linkintime.co.in; Investor Grievance E-mail ID: maitreyamedicare ipo@linkintime.co.in Contact Person: Shanti Gopalkrishnan; SEBI Registration Number: INR000004058 CIN No: U67190MH1999PTC118368	Ms Payal Mathur Maitreya Medicare Limited Nr. Someshwara Char Rasta, U.M Road, Surat City, Surat, Gujarat-395007 India. Telephone No.: +91 98798 89506; E-mail: cs@maitreyamedicareltd.com; Website: www.maitreyahospitals.com Applicants can contact the Compliance Officer, the BRLM or the Registrar to the Issue in case of any pre-issue or post-issue related problems, such as non-receipt of Allotment, non-credit of Allotment Equity Shares in the respective beneficiary account, non receipt of refund orders and non receipt of funds in electronic mode etc. All complaints, queries or comments received by Stock Exchange / SEBI shall be forwarded to the BRLM, who shall respond to the same.

AVAILABILITY OF RED HERRING PROSPECTUS: Investors should note that Investment in Equity Shares involves a degree of risk and an investor is advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the company at www.maitreyahospitals.com, the website of the BRLM to the Issue at www.gyrcapitaladvisors.com and the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#seme_offer respectively.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: MAITREYA MEDICARE LIMITED, Tel: +91 98798 89506, Registered office of the BRLM: GYR Capital Advisors Private Limited, Telephone: +91 8777564648 and at the selected locations of the Self Certified Syndicate Banks; Registered Brokers; Designated RTA Locations and Designated CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE Emerge and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

BANKER(S) TO THE ISSUE/REFUND BANK/ SPONSOR BANK: HDFC BANK LIMITED

LINK TO DOWNLOAD ABRIDGED PROSPECTUS: www.gyrcapitaladvisors.com

UPI: Retail Individual Bidders can also Bid through UPI Mechanism

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus

Place: Surat, Gujarat
Date: October 20, 2023

Disclaimer: MAITREYA MEDICARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Red Herring Prospectus dated October 19, 2023 has been filed with the Registrar of Companies, Gujarat and thereafter with SEBI and the Stock Exchanges. The RHP is available on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#seme_offer and is available on the websites of the BRLMs at www.gyrcapitaladvisors.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled "Risk Factors" beginning on page 32 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U. S. State Securities laws. The Equity Shares are being issued and sold outside the United States in "offshore transactions" in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

On behalf of Board of Directors
MAITREYA MEDICARE LIMITED
Sd/-
Dr. Narendra Singh Tanwar
Managing Director

KIRIN ADVISORS

(THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT. THIS DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. THIS PUBLIC ANNOUNCEMENT IS NOT INTENDED FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY OUTSIDE INDIA.)



MAITREYA MEDICARE LIMITED

Our Company was originally incorporated as 'Maitreya Medicare Private Limited' a private limited company under the Companies Act, 2013 at Surat Gujarat, pursuant to a certificate of incorporation dated March 28, 2019, issued by the Registrar of Companies, Central Registration Centre (CRC) ("RoC"). Thereafter, name of our Company was changed from 'Maitreya Medicare Private Limited' to 'Maitreya Medicare Limited', consequent to conversion of our Company from private to public company, pursuant to a special resolution passed by the shareholders of our Company on March 06, 2023, and a fresh certificate of incorporation consequent to change of name was issued by the RoC on March 30, 2023. Our Company's Corporate Identity Number is U24290GJ2019PLC107298. For details of change in Registered office of our Company, please refer to the chapter titled "History and Certain Corporate Matters" on page 166 of the Red Herring Prospectus dated October 19, 2023 filed with ROC.

Registered Office: Nr. Someshwara Char Rasta, UM Road, Surat, Gujarat-395007 India. Tel: +91 98798 89506; Website: www.maitreyahospitals.com; Contact Person: Ms. Payal Mathur, Company Secretary and Compliance Officer; E-mail id: cs@maitreyamedicareltd.com

Corporate Identity Number: U24290GJ2019PLC107298

OUR PROMOTERS: DR NARENDRA SINGH TANWAR, DR. PRANAV ROHITBHAI THAKER AND MR VIMALKUMAR NATVERLAL PATEL

THE ISSUE

INITIAL PUBLIC OFFER OF UP TO 18,16,000 EQUITY SHARES OF FACE VALUE ₹ 10 EACH (THE "EQUITY SHARES") OF MAITREYA MEDICARE LIMITED ("OUR COMPANY" OR THE "ISSUER") FOR CASH AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SECURITIES PREMIUM OF ₹ [●] PER EQUITY SHARE) ("ISSUE PRICE"), AGGREGATING UP TO ₹ [●] THOUSANDS (THE "ISSUE") OF WHICH 1,08,800 EQUITY SHARES AGGREGATING TO ₹ [●] THOUSANDS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"), THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 17,07,200 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AT AN ISSUE PRICE OF ₹ [●] PER EQUITY SHARE AGGREGATING UPTO ₹ [●] THOUSANDS IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE "PUBLIC ISSUE" AND THE "NET ISSUE" WILL CONSTITUTE 26.80 % AND 25.19 % RESPECTIVELY OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

The Issue is being made in terms of Chapter IX of the SEBI (ICDR) Regulations, 2018, as amended from time to time. This Issue is being made by our company in terms of Regulation of 229 (1) of SEBI ICDR Regulations read with Rule 19(2)(b)(i) of SCRR wherein not less than 25% of the post – issue paid up equity share capital of our company are being offered to the public for subscription. (For further details please see section titled "Issue Structure" beginning on page 311 of the Red Herring Prospectus). A copy of Red Herring Prospectus is delivered for filing to the Registrar of Companies as required under section 26(4) of the Companies Act, 2013.

QIB PORTION: NOT MORE THAN 50.00% OF THE NET ISSUE | NON-INSTITUTIONAL PORTION: NOT LESS THAN 15.00% OF THE NET ISSUE
RETAIL PORTION: NOT LESS THAN 35.00% OF THE NET ISSUE | MARKET MAKER PORTION: UPTO 17,07,200 EQUITY SHARES, [●]% OF THE ISSUE

PRICE BAND: ₹ 78 TO ₹ 82 PER EQUITY SHARE OF FACE VALUE ₹ 10/- EACH

THE FLOOR PRICE IS 7.8 TIMES OF THE FACE VALUE AND THE CAP PRICE IS 8.2 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

BIDS CAN BE MADE FOR A MINIMUM OF 1600 EQUITY SHARES AND IN MULTIPLES OF 1600 EQUITY SHARES

Risk to Investors:

- We are highly dependent on our doctors, nurses and other healthcare professionals, as well as other key personnel and the loss of, or inability to attract or retain, such persons could adversely affect our business and results of operations.
- The Merchant Banker associated with the issue has handled 16 public issues in the past two years out of which no issues closed below the Issue Price on Listing Date.
- Average cost of acquisition of Equity Shares held by the Promoters Dr. Narendra Singh Tanwar, Mr. Vimalkumar Natverlal Patel and Dr. Pranav Rohitbhai Thaker is ₹ 2.40, ₹ 0.02 and ₹ 0.02 respectively per Equity Share and the Issue Price at the Upper end of the Price Band is ₹ 82 per Equity Share.
- The Price /Earnings ratio based on the Diluted EPS for year ended Sept 2023 for the company at the upper end of the Price Band is ₹ 16.02.
- Weighted Average Return on Net worth for Fiscals 2023, 2022 and 2021 is 45.99%.
- We may generate revenue from the arrangements with government sponsored health schemes, any adverse change in these regulations/government policies related to such schemes may adversely affect our business, results of operations, cash flows and prospects.
- We are yet to apply for approvals and licenses for our proposed Valsad hospital in our subsidiary company Maitreya Hospital Pvt Ltd and can be applied only after operations are commenced, so in case we are unable to obtain required applicable approvals and licenses on time it will effect the company's revenues, credibility and future plans.
- Our operations are geographically located in one area at present and any localized social unrest, natural calamities, etc. could have material adverse effect on business and financial operations.

BASIS FOR ISSUE PRICE

Investors should read the following summary with the sections titled "Risk Factors", the details about the company under the section titled "Our Business" and its financial statements under the section titled "Restated Financial Statements" beginning on pages 32, 139 and 199 respectively, of the RHP to get a more informed view before making any investment decisions. The trading price of the Equity Shares of Our Company could decline due to these risk factors and you may lose all or part of your investments.

The Price Band/ Issue Price shall be determined by our Company in consultation with the BRLM on the basis of the assessment of market demand for the Equity Shares through the Book Building Process and on the basis of the quantitative and qualitative factors as described in this section. The face value of the Equity Shares is ₹ 10/- each and Issue Price is 7.8 times of the face value at the lower end of the Price Band and 8.2 times of the face value at the upper end of the Price Band.

Qualitative Factors

We believe that the following business strengths allow us to successfully compete in the industry:

- Key Multi-specialty tertiary and quaternary healthcare provider providing well diversified and specialized service offerings and strong brand recognition;
- Regional leadership through delivering clinical excellence and affordable healthcare in South Gujarat;
- Quality health care services;
- Experienced senior management team;
- Track Record of stable operating and financial performance and growth;
- Ability to attract, train and retain high quality doctors, consultants and medical support staff;

For further details regarding some of the qualitative factors, which form the basis for computing the Issue Price, please refer chapter titled "Our Business" beginning on page 139 of the Red Herring Prospectus.

Quantitative Factors

The information presented below relating to our company is based on the Restated Financial Statements of the Company for the period ending September 30, 2023 and financial year ended March 31, 2023, 2022 and 2021. For more details, please refer the section titled "Restated Financial Statements" beginning on page 199 of the Red Herring Prospectus.

Investors should evaluate our Company taking into consideration its earnings and based on its growth strategy. Some of the quantitative factors which may form the basis for computing the Issue Price are as follows:

1. Basic and Diluted Earnings per Share ("EPS") (Face Value of ₹ 10/- each)

Financial	Basic & Diluted	
	EPS (in ₹)	Weight
Financial year ending on March 31, 2021	8.06	1
Financial year ending on March 31, 2022	1.71	2
Financial year ending on March 31, 2023	7.93	3
Weighted Average	5.88	
For the period ended September 30, 2023	5.12	

Notes:

a. Basic EPS has been calculated as per the following formula:

$$\text{Basic EPS (₹)} = \frac{\text{Net profit/(loss) as restated, attributable to Equity Shareholders}}{\text{Weighted average number of Equity Shares outstanding during the year/period}}$$

b. Diluted EPS has been calculated as per the following formula:

$$\text{Diluted EPS (₹)} = \frac{\text{Net profit/(loss) as restated, attributable to Equity Shareholders}}{\text{Diluted Weighted average number of Equity Shares outstanding during the year/period}}$$

c. The figures disclosed above are based on the Restated Financial Statements of the Company.

d. Basic and Diluted EPS calculations are in accordance with Accounting Standard 20 - "Earnings per Share", issued by the Institute of Chartered Accountants of India.

e. The above statement should be read in conjunction with Significant Accounting Policies and Notes to Restated Financial Statements as appearing in the section titled "Restated Financial Statements" beginning on page 199 of the Red Herring Prospectus.

2. Price Earnings Ratio ("P/E") in relation to the Price Band of ₹ 78 to ₹ 82 per Equity Share of Face Value of ₹ 10/- each fully paid up:

Particulars	P/E Ratio at the Floor Price	P/E Ratio at the Cap Price
P/E ratio based on the Basic and Diluted EPS, as at March 31, 2023	9.83	10.34
P/E ratio based on the Basic and Diluted EPS, as at March 31, 2022	45.61	47.95
P/E ratio based on the Basic and Diluted EPS, as at March 31, 2021	9.68	10.17
P/E ratio based on the Weighted Average EPS, as restated	13.26	13.95

*The details shall be provided post the fixing of the price band by our company at the stage of filing of the price band advertisement.

Industry Price / Earning (P/E) Ratio

Industry P/E Ratio	P/E Ratio
Highest	56.92
Lowest	31.72
Industry Average	44.32

Notes:

i. The P/E Ratio of our company has been computed by dividing Issue Price with EPS.

ii. For the purpose of industry, we have considered those companies which are engaged in the similar line of business segment as of our company, however, they may not be exactly comparable in terms of product portfolio or the size of our company. The peers have been included for the purpose of broad comparison.

iii. The industry high and low has been considered from the industry peer set provided later in this chapter. The industry composite has been calculated as the arithmetic average P/E of the industry peer set disclosed in this section.

iv. The P/E Ratio of the peer company is based on the Consolidated financial results for the F.Y. 2022-2023 and the Stock Exchange data dated August 21, 2023.

3. Return on Net worth (RONW)

Period / Year ended	RoNW (%)	Weight
Financial Year ended on March 31, 2021	103.45%	1
Financial Year ended on March 31, 2 2022	18.02%	2
Financial Year ended on March 31, 2 2023	45.49%	3
Weighted Average	45.99%	
For the period ended September 30, 2023	22.72%	

Notes:

i) Return on Net worth has been calculated as per the following formula:

$$\text{RONW} = \frac{\text{Net profit/loss after tax as restated}}{\text{Net worth excluding preference share capital and revaluation reserve}}$$

ii) Weighted Average= Aggregate of year-wise weighted RoNW i.e. (RoNW x Weights) for each year
Aggregate of Weights

iii) The figures disclosed above are based on the Restated Financial Statements of the company.

4. Net Asset Value (NAV) Per Equity Share

Financial Year	NAV (in ₹)
NAV as at March 31, 2021	3862.16
NAV as at March 31, 2022	4711.12
NAV as at March 31, 2023	17.42
NAV for the period ending Sept 30, 2023	22.55
NAV per Equity share after the Issue	[●]
Issue Price per Equity Share	[●]

Notes:

i. Net Asset Value has been calculated as per the following formula:

$$\text{NAV} = \frac{\text{Net worth excluding preference share capital and revaluation reserve}}{\text{Outstanding number of Equity shares at the end of the year}}$$

ii. The figures disclosed above are based on the Restated Financial Statements of the company.

iii. Network is computed as the sum of the aggregate of paid up equity share capital, all reserves created out of the profits, securities premium account received in respect of equity shares and debit or credit balance of profit and loss account.

iv. Issue Price per Equity Share will be determined by our company in consultation with the BRLM.

5. Comparison of Accounting Ratios with Industry Peers

The following peer group has been determined on the basis of companies listed on Indian stock exchanges, whose business profile is comparable to our businesses:

Name of the Company	Face Value (₹)	Current Market Price*	EPS (₹) Basic /Diluted	P/E Ratio*	RoNW (%)	Book Value Per Share	Total Income (₹ in Thousands)
Maitreya Medicare Limited (Our company)	10.00	[●]	7.93	[●]	45.49%	17.42	399491
Peer Group							
Shalby Limited	10	264.45	7.48	35.35	7.30%	86.44	72,73820
KMC Speciality Hospitals (India) Limited	1	84.51	1.64	51.53	23.51%	6.96	13,82197
Global Health Limited	2	776.30	12.57	61.76	13.43%	90.54	2,75,91631

Notes:

i. Source: All the financial information for listed industry peers mentioned above is sourced from the financial results of the aforesaid companies for the year ended March 31, 2023 and stock exchange data dated Sept 30, 2023 to compute the corresponding financial ratios. Current Market Price is as on 19th October, 2023. For our company, we have taken Current Market Price as the issue price of equity share. Further, P/E ratio is based on the current market price of the respective scrips.

ii. The EPS, NAV, RoNW and Total Income of our company are taken as per Restated Financial Statement for the Financial year 2022-2023.

iii. The NAV per share is computed as the closing net worth divided by the weighted average number of paid-up equity shares as on March 31, 2023.

iv. RoNW has been computed as net profit after tax divided by closing network.

v. Net worth has been computed in the manner as specified in Regulation 2(1) (hh) of SEBI (ICDR) Regulations, 2018.

vi. The face value of Equity Shares of our company is ₹ 10/- per Equity Share and the Issue Price is [●] times the face value of equity share.

For further details see section titled "Risk Factors" beginning on page 32 of the RHP and the financials of the Company including profitability and return ratios, as set out in the section titled Auditors Report and Financial Information of Our Company beginning on page 199 of the RHP for a more informed view.

Key financial and operational Performance Indicators ("KPIs")

Our company considers that KPIs included herein below have a bearing for arriving at the basis for Offer Price. The KPIs disclosed below have been used historically by our Company to understand and analyze the business performance, which in result, help us in analyzing the growth of our company.

The KPIs disclosed below have been approved by a resolution of our Audit Committee August 22, 2023 and the members of the Audit Committee have verified the details of all KPIs pertaining to our Company. Further, the KPIs herein have been certified by M/s. Saherwala & Co. Chartered Accountants, by their certificate dated August 22, 2023 vide UDIN 2312236BGTOEI3702. Further, the members of the Audit Committee have confirmed that there are no KPIs pertaining to our Company that have been disclosed to any investors at any point of time during the three years period prior to the date of filing of the Red Herring Prospectus.

For the details of our key performance indicators, see sections titled "Risk Factors", "Our Business" and "Management's Discussion and Analysis of Financial Condition and Results of Operations – Key Performance Indicators" on pages 32, 139 and 257, respectively of the RHP. We have described and defined them, where applicable, in "Definitions and Abbreviations" section on page 6 of the RHP. Our Company confirms that it shall continue to disclose all the KPIs included in this section on a periodic basis, at least once in a year (or any lesser period as determined by the Board of our Company), for a duration of one year after the date of listing of the Equity Shares on the Stock Exchange or till the complete utilisation of the proceeds of the Fresh Issue as per the disclosure made in the Objects of the Issue, whichever is later or for such other duration as may be required under the SEBI ICDR Regulations. Further, the ongoing KPIs will continue to be certified by a member of an expert body as required under the SEBI ICDR Regulations.

Key metrics like revenue growth, EBITDA Margin, PAT Margin and few balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company

Consolidated KPI Indicators

(Amount in thousands, except EPS, % and ratios)

Key Financial Performance	September 30, 2023	Fiscal 2023	Fiscal 2022	Fiscal 2021
Revenue from Operations	2,47,936.13	3,93,799.63	4,94,116.44	5,66,136.29
EBITDA ⁽ⁱ⁾	44,936.76	77,323.27	35,033.41	74,595.67
EBITDA Margin (%) ⁽ⁱⁱ⁾	18.12%	19.64%	7.09%	13.18%
Restated profit for the period/year	25,405.00	42,264.88 1	1,363.10	42,434.39
Restated profit for the period/year Margin (%) ⁽ⁱⁱⁱ⁾	10.25%	10.73%	2.30%	7.50%
Return on Average Equity ("RoAE") (%) ^(iv)	15.01	15.83%	63%	55.47%
Return on Capital Employed("RoCE") (%) ^(v)	23.75	42.71%	17.22%	47.91%

Notes:

i) EDITDA is calculated as restated profit for the period/ year plus tax expense plus depreciation and amortization plus finance costs plus exceptional items.

ii) EBITDA Margin is calculated as EBITDA divided by revenue from operations.

iii) Restated profit for the period / year margin is calculated as restated profit for the period / year divided by revenue from operations.

iv) RoAE is calculated as Net profit after tax divided by Average Equity.

v) RoCE is calculated as Earnings before interest and taxes (EBIT) divided by Capital Employed.



(Please scan this QR Code to view the RHP and Abridged Prospectus)

આમોદનો જર્જરિત હાઈ-વે
દોઢ માસમાં નવીનીકરણ થઈ
જશે: ધારાસભ્ય ડી.કે. સ્વામી

આમોદ, તા.૨૦
આમોદ પાસેથી પસાર થતો નેશનલ હાઈવે નંબર ૬૪ છેલ્લા ઘણા સમયથી બિસ્માર બન્યો હતો. બિસ્માર રોડના કારણે વાહનચાલકો તેમજ રાહદારીઓ અને સ્થાનિક વેપારીઓમાં હાઈવે ઓથોરિટી સામે રોષ જોવા મળ્યો હતો. ત્યારે આજે જંબુસર વિધાનસભાના ધારાસભ્ય ડી.કે.સ્વામીના હસ્તે રોડનું ખર્તમુહૂર્ત કરવામાં આવતા વાહનચાલકો સહિત સ્થાનિકોમાં આનંદની લાગણી પ્રસરી જવા પામી હતી.

આમોદ પાસેથી પસાર થતા નેશનલ હાઈ-વે ૭.૩૩ કરોડના ખર્ચે ત્રણ અલગ અલગ સેક્શનમાં બનાવવામાં આવશે. જેમાં આમોદના મલ્લાં તળાવથી બનીસી નાળા સુધી પાંચ લેયરમાં બનાવવામાં આવશે. દેરોલથી કંધારીયા બે લેયર તેમજ સુડી-સમની સેક્શન પાંચ લેયરમાં રોડ બનાવવામાં આવશે. આ ઉપરાંત બિસ્માર રોડ નીચે ખોદકામ કરી કાળી માટી કાઢી તેમાં પીળી માટીનો ઉપયોગ કરવામાં આવશે. નેશનલ હાઈ-વે ના ખર્તમુહૂર્ત પ્રસંગે આમોદ તાલુકા પંચાયત પ્રમુખ હેમા પરમાર, ભરૂચ જિલ્લા ભાજપ મંત્રી ઉર્મિલા પઢિયાર, તાલુકા ભાજપ મહામંત્રી દીપક ચૌહાણ, તાલુકા પંચાયત સદસ્ય સંજયસિંહ રાજ સહિત ભાજપના કાર્યકરો મોટી સંખ્યામાં ઉપસ્થિત રહ્યા હતા. આ પ્રસંગે ધારાસભ્ય ડી.કે.સ્વામીએ રોડની નવીનીકરણની કામગીરી દોઢ મહિનામાં પૂર્ણ કરવામાં આવશે તેનું જણાવ્યું હતું.

આત્મહત્યાનાં દુષ્ક્રમણનાં કેસમાં કતારગામનાં વિપુલ વોરાનાં જામીન કોટે ફગાવ્યા

સુરતઃ ભાગીદારીમાં શરૂ કરેલા ટોબેકોના ધંધાના હિસાબની પદાણી ઉધરાણીમાં ભાગીદારે કરેલા આત્મહત્યાના દુષ્ક્રમણ કેસમાં કતારગામનાભાગીદાર વિપુલ વોરાના જામીન કોટે ફગાવી દીધા હતા. સરકારી વકીલ અરવિંદ વસોયાએ દલીલો કરી હતી.

સામુણ રોડ અમરોલી શ્રી ગણેશ રેસીડેન્સીમાં રહેતા રસીક બોધા વોરા(ઉ.વ.47) કારેલી ગામે ડાયમંડ યુનીટમાં સુપરવાઈઝર તરીકે નોકરી કરતા હતા. રસીક વોરા અને સંબંધી વિપુલ ઠાકરશી વોરા(રહે.માધવાનંદ સોસા. કતારગામ)એ ભાગીદારીમાં રિડી સિથ્લી ટોબેકોના નામે ભાગીદારીમાં વેપાર શરૂ કર્યો હતો. વર્ષ 2020માં રસીક વોરા પાસેથી વિપુલ વોરાએ ભાગીદારીમાં દુકાન ચાલુ કરી ત્યારથી લઈને આજદીન સુધીના હિસાબ પેટે રૂ.૧૦ લાખ માંગતા હતા. વિપુલ વોરા અને તેમના મિત્ર હિરેન કળસરીયા રસીકભાઈના ઘરે જઈ નાણાની ઉધરાણી કરતા હતા. જેથી વિપુલ વોરા અને હિરેન કળસરિયાની પદાણી ઉધરાણીથી કંટાળી રસીક વોરાએ પોતાના ડાયમંડ યુનીટમાં સ્પુસાઈઝ નોટ લખી આત્મહત્યા કરી લીધી હતી. મોલપાડ પોલીસે વિપુલ વોરા અને હિરેન કળસરિયા સામે દુષ્ક્રમણની ફરિયાદ નોંધાવી હતી. આ કેસમાં જેલમાં બંધ વિપુલ વોરાએ જામીન ઉપર મુકત થવા કરેલી અરજ કોટે ફગાવી હતી. સરકારી વકીલ અરવિંદ વસોયાએ દલીલો કરી હતી.

રાજકોટમાં દર્દીનો તબીબી રેકૉર્ડ દર્શાવતા આભા કાંડ બનાવવાનો પ્રારંભ, ગુજરાતમાં પ્રથમ જિલ્લો

રાજકોટઃ ભારત સરકારે આયુષ્માન ભારત હેલ્થ એકાઉન્ટ (ABHA) તરીકે ડિજિટલ હેલ્થ આર.ડી. લોન્ચ કર્યું છે. ABHA કાર્ડથી દર્દી ભારતભરના સરકારી દવાખાનામાં તબીબી રેકૉર્ડ આસાનીથી બતાવી શકશે. આ ઉપરાંત દર્દીઓને દવાખાનાની લાંબી લાઈનોમાં ઉભા રહેવાની હાડમારીમાંથી છટકારો મળશે. ગુજરાતમાં સૌ પ્રથમ રાજકોટની સિવિલ હોસ્પિટલમાં ABHA કાર્ડ બનાવવાનો આરંભ થઈ ગયો છે.

રાજકોટ સિવિલ હોસ્પિટલના સુપ્રિટેન્ડેન્ટ આર.એસ. ત્રિવેદીએ જણાવ્યું કે, ગુજરાતમાં સૌ પ્રથમ આ સુવિધાનો રાજકોટથી પ્રારંભ થઈ ગયો છે. દરરોજ 100 થી 150 જેટલા આભા કાર્ડ બની રહ્યાં છે. ખાસ કરીને જાગૃત દર્દીઓ આભા કાર્ડ મેળવવા લાગ્યા છે. સરકારની આ સુવિધાને શંકરમાં કેવો પ્રતિસાદ સાંપડી રહ્યો છે? તે જાણવા માટે ગાંધીનગર સ્થિત આરોગ્ય વિભાગમાંથી સંયુક્ત નિયામકની ટીમે સિવિલ હોસ્પિટલની મુલાકાત લીધી હતી. જ્યાં સુપ્રિટેન્ડેન્ટ સહિત તબીબી સ્ટાફને વધુમાં વધુ લોકો ABHA કાર્ડ મેળવતા થાય તેવી વ્યવસ્થા અને સેવા પૂરી પાડવા તાકીદ કરી છે.

Continued on next page...

» પહેલા પાનાનું શેષ

કાયદા પંથ 25

સુત્રોએ જણાવ્યું હતું કે રાજકીય પક્ષોને મોકલવામાં આવેલા પત્રમાં તેમણે તેમની સાથે ‘પરસ્પર સંપત તારીખ’ પર વાતચીત કરવાની માંગ કરી છે. તેમણે કહ્યું કે પક્ષકારોને આગામી ત્રણ મહિનામાં તેમના મતવ્યો લેખિતમાં મોકલવાનો વિકલ્પ પણ આપવામાં આવ્યો છે. જસ્ટિસ રિતુ રાજ અવસ્થીની આગેવાની હેઠળનું લો કમિશન કાર્યકાળ વધારીને અથવા ઘટાડીને તમામ વિધાનસભા ચૂંટણીઓનું સંકલન કરવા માટે એક કોમ્યુલ્કા પર કામ કરી રહ્યું છે, જેથી આ ચૂંટણીઓ 2029ની લોકસભા ચૂંટણીની સાથે યોજવામાં આવે.

ભારતીયોને અવકાશમાં

ISROના આ ‘સેમી-કાઈનલ’ ટેસ્ટ ફ્લાઈટ મિશનનો હેતુ ગગનયાન મિશન હેઠળ ભારતીય અવકાશયાત્રીઓને પૃથ્વી પર પાછા લાવવા માટે ક્રૂ મોડ્યુલ અને ક્રૂ રેસ્ક્યુ સિસ્ટમના સલામતી ધોરણોનો અભ્યાસ કરવાનો છે. ગગનયાન મિશનનો ઉદ્દેશ્ય 2025માં ત્રણ દિવસના મિશનમાં 400 કિલોમીટરની ઉંચાઈએ પૃથ્વીની નીચલી ભ્રમણકક્ષામાં માનવોને મોકલવાનો અને તેમને સુરક્ષિત રીતે પૃથ્વી પર પાછા લાવવાનો છે. શનિવારે, ISRO તેના ટેસ્ટ બ્લીકલ - ‘ડેમોન્સ્ટ્રેશન (TV-D1), સિંગલ-સ્ટેજ લિક્વિડ પ્રોપલ્શન રોકેટના સફળ પ્રક્ષેપણનો પ્રયાસ કરશે. આ ક્રૂ મોડ્યુલ સાથે પરીક્ષણ અવકાશયાન મિશન એક્ઝેટર ગગનયાન કાર્યક્રમ માટે એક મહત્વપૂર્ણ સીમાચિહ્નરૂપ છે કારણ કે ગઈકાલે લગભગ સમગ્ર સિસ્ટમને પરીક્ષણ માટે સંકલિત કરવામાં આવી છે. ઈસરોએ શુક્રવારે તેની વેબસાઈટ પર માહિતી આપી હતી કે, ‘21 ઓક્ટોબરે સવારે 8 વાગ્યે ટીવી-ડી1 ટેસ્ટ ફ્લાઈટ લોન્ચ કરવા માટેનું કાઉન્ટડાઉન શુક્રવારે સાંજે 7 વાગ્યે શરૂ થઈ ગયું છે.’

ISROએ કહ્યું કે આ પરીક્ષણ ફ્લાઈટની સફળતા બાકીના પરીક્ષણો અને માનવરહિત મિશન માટે પાયો નામશે, જે પ્રથમ ગગનયાન કાર્યક્રમ શરૂ કરશે. ‘ક્રૂ મોડ્યુલ’ એ રોકેટમાં પેલોડ છે, અને તે પૃથ્વી જેવા વાતાવરણ સાથે અવકાશમાં અવકાશયાત્રીઓ માટે રહેલા યોગ્ય જગ્યા છે. તેમાં દબાણયુક્ત ધાતુનું ‘ઑટરિક માળખું’ અને થર્મલ પ્રોટેક્શન સિસ્ટમ્સ સાથેનું દબાણ વિનાનું ‘બાહ્ય માળખું’ હોય છે. શનિવારે પ્રથમ ટેસ્ટ ફ્લાઈટ દરમિયાન, ‘ક્રૂ મોડ્યુલ’માં વિવિધ પ્રણાલીઓના પ્રદર્શનનું મૂલ્યાંકન કરવા માટે ડેટા મેળવવામાં આવશે જે વૈજ્ઞાનિકોને વાહનના પ્રદર્શન વિશે માહિતી મેળવવામાં મદદ કરશે.

કેનેડા ભારત

કારણ કે કેનેડાના વિદેશ મંત્રી મેલાની જોલીએ કહ્યું છે કે કેનેડાએ નિર્ણય લીધો છે કે તે ભારતના આ પગલા પર કોઈ પ્રતિક્રિયા નહીં આપે.

ભારતમાં કેનેડિયન

શોપણનો સામનો કરવો પડીશ કે છે. એડવાઈઝરીમાં કહેવામાં આવ્યું છે કે દિલ્હી-એનસીઆરમાં અજાણ્યા લોકો સાથે વાત ન કરશો અને તેમની સાથે તમારી અંગત માહિતી શેર ન કરશો. ભીડવાળા વિસ્તારોમાં જવાનું ટાળો અને જાહેર પરિવહનનો ઉપયોગ પણ ટાળો. જ્યારે પણ તમે બહાર જાવ, ત્યારે તમારા મિત્રો અથવા પરિવારને તમારી મુસાફરીની યોજનાઓ વિશે જણાવો.

રાજદ્વારીઓને પાછા

વિદેના કન્વેન્શનનું ઉલ્લંઘન કરવાનો આરોપ લગાવ્યો હતો. વિદેશ મંત્રી મેલાની જોલીએ ગુરુવારે કહ્યું કે બંને દેશો વચ્ચે ચાલી રહેલા વિવાદ વચ્ચે અમે તેમના 41 રાજદ્વારીઓ અને 42 તેમના અશ્વિતોને ભારતથી પાછા બોલાવ્યા છે. વિદેશ મંત્રાલયે કહ્યું, ‘અમે આંતરરાષ્ટ્રીય ધોરણોના ઉલ્લંઘનમાં સમાનાતને લાગુ કરવાના કોઈપણ પ્રયાસને નકારીએ છીએ.’ MEAના નિવેદનમાં કહેવામાં આવ્યું છે કે ભારત અને કેનેડા વચ્ચેના સંબંધોની સ્થિતિ તેમજ ભારતની આંતરિક બાબતોમાં ઓઢવાની સતત હાજરી નવી દિલ્હી અને ઓટાવામાં પરસ્પર રાજદ્વારી હાજરીમાં ‘સમાનાતની’ ખાતરી આપે છે. વિદેશ મંત્રાલયના નિવેદનમાં કહેવામાં આવ્યું છે કે, તેના અમલીકરણની વિગતો અને રીતભાત પર કામ કરવા માટે ભારતે ગયા મહિને કેનેડા સાથે વાટાઘાટો કરી હતી. જેમાં જમાવ્યું છે. સમાનતાના અમલીકરણમાં ભારતની કાર્યવાહી રાજદ્વારી સંબંધો પર વિદેના કન્વેન્શનની કલમ 11.1 સાથે સંપૂર્ણ રીતે સુસંગત છે.

ચૂપકો મહિલાઓની

એવું ન વિચારવું જોઈએ કે માત્ર એક બાળકી જ શોપણનો

શનિવાર તા.૨૧ ઓક્ટોબર ૨૦૨૩



કલકત્તા હાઈકોર્ટે તેના ચુકાદામાં વધુમાં જણાવ્યું હતું કે, “કિશોરોને સેક્સ સામાન્ય છે પરંતુ જાતીય ઈચ્છા અથવા આવી ઈચ્છાનું ઉત્તેજન વ્યક્તિની અમુક ક્રિયાઓ પર આધાર રાખે છે, કદાચ પુરુષ એન્ડ્રોજેનિક સ્ટીરોઈડ સ્તરોજન હોમાંન છે, જે મુખ્યત્વે પુરુષોના અંડકોષ અને સ્ત્રીઓમાં અંડકોશ દ્વારા અને પુરૂષો અને સ્ત્રીઓ બંનેમાં મૂત્રપિંડ પાસેની ગ્રંથીઓ દ્વારા ઓછી માત્રામાં સ્ત્રાવ થાય છે. હાયપોથાલેમસ અને ક્હોત્વાદક ગ્રંથીઓ ટેસ્ટોસ્ટેરોનની માત્રાને નિયંત્રિત કરે છે, જે મુખ્યત્વે સેક્સ અથવા કામવાસના (પુરુષોમાં) માટે જવાબદાર છે.

તે શરીરમાં અસ્તિત્વ ધરાવે છે, તેથી જ્યારે સંબંધિત ગ્રંથિ ઉત્તેજના દ્વારા સક્રિય થાય છે, ત્યારે જાતીય ઈચ્છા જાગૃત થાય છે. પરંતુ સંબંધિત જવાબદાર ગ્રંથિનું સક્રિયકરણ આપોઆપ થતું નથી. કારણ કે તેને આપણી દ્રષ્ટિ, શ્રવણ, શૃંગારિક સામગ્રી વાંચવા અને વિજાતીય સાથેની ક્રિયાપ્રતિક્રિયામાંથી ઉત્તેજનાની જરૂર છે. “જાતીય ઈચ્છા આપણી પોતાની ક્રિયાઓ દ્વારા ઉત્તેજીત થાય છે.”

ઈન્ડિયન ત્રણ

હમાસના સ્થાનો પર મિસાઈલો છોડી હતી. હમાસની 100 થી વધુ જગ્યાઓને નિશાન બનાવવામાં આવી હતી અને તેના સશસ્ત્ર આતંકવાદીઓ માર્યા ગયા હતા. સ્થાનિક મીડિયા અનુસાર, ઈઝરાયેલ લેબનીઝ સરહદે તેના ઉત્તરીય ભાગમાં કિરયાત શમોના શહેરના રહેવાસીઓને ખાલી કરવાનો આદેશ આપ્યો છે. વસતવમાં, હમાસ સિવાય, ઈઝરાયેલ લેબનોનમાં સરહદ પાર હિઝબુલ્લાહ લડવૈયાઓ સાથે પણ

લડી રહ્યું છે. હિઝબુલ્લાહ સંગઠન અને અન્ય સહયોગી પેલેસ્ટિનિયન જૂથો ઉત્તરી ઈઝરાયેલને નિશાન બનાવીને વારંવાર રોકેટ અને મિસાઈલ હુમલાઓ કરી રહ્યા છે. કિરયાત શમોનાની વસ્તી 20,000 થી વધુ છે અને તે સરહદની વાઘી લગભગ 2 કિમી દૂર છે.7 ઓક્ટોબરે હમાસના હુમલા બાદ ઈઝરાયેલ અત્યાર સુધી કહેતું આવ્યું છે કે તે તેને (હમાસ)ને સંપૂર્ણ રીતે નષ્ટ કરી દેશે. આ દરમિયાન ઈઝરાયેલના સંરક્ષણ મંત્રી યોવ ગાલાન્તે પોતાના સેનિકોને ગાઝાની અંદરથી નિરીક્ષણ કરવા માટે તૈયાર રહેવાનો આદેશ આપ્યો છે. બીજા તરફ ગાઝા પટ્ટીથી ઈઝરાયેલ તરફ રોકેટ છોડવામાં આવી રહ્યા હોવાની તસવીરો પણ સામે આવી છે. ગુરુવારે, ઈઝરાયેલની આયર્ન ડોમ એર ડિફેન્સ સિસ્ટમએ ગાઝાથી એરેલ્લોન શહેરમાં છોડેલા રોકેટને અટકાવ્યું હતું.

હમાસ સંચાલિત હાઝા આરોગ્ય મંત્રાલયના જણાવ્યા અનુસાર, યુદ્ધમાં અત્યાર સુધીમાં 4,137 પેલેસ્ટિનિયન માર્યા ગયા છે અને 13 હજારથી વધુ લોકો ધાયલ થયા છે. તે જ સમયે, ઈઝરાયેલમાં 1400 થી વધુ લોકોએ જીવ ગુમાવ્યો છે. ઈઝરાયેલની સેનાના પ્રવક્તાના જણાવ્યા અનુસાર એવું માનવામાં આવે છે કે

હમાસે 203 લોકોના પરિવારજનોને બંધક બનાવ્યા છે. ઈઝરાયેલની સેનાનું કહેવું છે કે ગાઝામાં બંધક બનાવવામાં આવેલા 200 લોકોમાં 18 વર્ષથી ઓછી ઉંમરના 20 બાળકો પણ સામેલ છે.ઈઝરાયેલના સંરક્ષણ પ્રધાને શુક્રવારે (20 ઓક્ટોબર) કહ્યું હતું કે હમાસ આતંકવાદી જૂથને ખતમ કર્યા પછી ઈઝરાયેલી સેનાની ગાઝામાં જીવનને નિયંત્રિત કરવાની કોઈ યોજના નથી. તેમણે કહ્યું કે હમાસ સાથે ઈઝરાયેલનું યુદ્ધ ત્રણ તબક્કામાં હશે. ઈઝરાયેલના સંરક્ષણમંત્રી યોવ ગેલેન્તે તેલ અવીવમાં સંરક્ષણ સમિતિની બેઠકમાં ગાઝાપટ્ટીમાં ઈઝરાયેલનો વોર પ્લાન જણાવ્યો. તેમણે કહ્યું- અમે પહેલા હમાસની સૈન્ય ક્ષમતા અને સરકાર ચલાવવાની ક્ષમતાને નષ્ટ કરીશું. બીજા શબ્દોમાં કહીએ તો અમે હમાસને જરૂરખોથી ઉમેરી નાખીશ સેટેલાઈટ તસવીરોમાં જોવા મળેલી તબાહી ગાઝામાં થયેલા વિનાશની સેટેલાઈટ તસવીરો સામે આવી છે. Maxar Technologiesએ ગુરુવારે આ તસવીરો જાહેર કરી હતી. તસ્વીરોમાં વિસ્ફોટોના કારણે આ વિસ્તારમાં મિસાઈલના પ્રાઉન્ડ બ્લોક્સ અને ધુમાડાના ગોંટગોટા દેખાઈ રહ્યા છે. ચિત્રો

બતાવે છે કે લોકો ગુરુવારે ગાઝા શહેરની બે શાળાઓ અને દેર અલ-બાલાહમાં એક શાળાના આંગણમાં આશ્રય લેતા હતા. ચિત્રો એ પણ બતાવે છે કે ગાઝા સિટીમાં માર્જોઝ સ્પ્રીટ ક્રશ્તાન વિસ્તરી રહ્યું છે, જેમાં ટ્રેક્ટર નવી કબરો માટે જગ્યા બનાવવા માટે તાજી માટી ફેરવે છે. તે જ સમયે, અમેરિકી સંરક્ષણ પ્રધાન લોયડ જૅ.ઓસ્ટિને કહ્યું છે કે તેમણે તેમના ઈઝરાયેલી સમકક્ષ Yoav Gallant સાથે અમેરિકા દ્વારા ઈઝરાયેલને આપવામાં આવતી સુરક્ષા સહાય અંગે વાત કરી છે. યુએન ચીફ રફાહ સરહદે પહોંચ્યા, યુદ્ધવિરામનો પુનરોચ્ચાર કર્યો દરમિયાન, શુક્રવારે યુએન સેક્રેટરી જનરલ એન્ટોનિયો ગુટેરેસ ઈજિપ્ત અને ગાઝા પટ્ટી વચ્ચેની રફાહ સરહદે પહોંચ્યા હતા. તેમણે તમામ આંતરરાષ્ટ્રીય પક્ષોને ગાઝામાં પેલેસ્ટિનીઓને માનવતાવાદી સહાય પહોંચે તેની ખાતરી કરવા સાથે મળીને કામ કરવા હાકલ કરી હતી. યુએનના વડાએ ફરી એકવાર લડતા પક્ષો તરફથી યુદ્ધવિરામ માટેના તેમના આઘ્વાનનો પુનરોચ્ચાર કર્યો.

ઇઝરાયેલે 900

હતા. મંત્રાલયે ગુરુવારે રાત્રે જણાવ્યું હતું કે, ગાઝા શહેરમાં ગ્રીક

...continued from previous page

KPI	Explanation
Revenue from operations:	Revenue from operations represents the total turnover of the business as well as provides information regarding the year over year growth of our Company.
EBITDA:	EBITDA is calculated as Restated profit / loss for the period plus tax expense plus depreciation and amortization plus finance costs and any exceptional items. EBITDA provides information regarding the operational efficiency of the business of our Company
EBITDA margin:	EBITDA Margin the percentage of EBITDA divided by revenue from operations and is an indicator of the operational profitability of our business before interest, depreciation, amortisation, and taxes. Restated profit for the period / year: Restated profit for the period / year represents the profit / loss that our Company makes for the financial year or during a given period. It provides information regarding the profitability of the business of our Company.
Restated profit for the period / year margin:	Restated profit for the period / year Margin is the ratio of Restated profit for the period / year to the total revenue of the Company. It provides information regarding the profitability of the business of our Company as well as to compare against the historical performance of our business.
Return on Average Equity ("RoAE"):	RoAE refers to Restated profit for the period / year divided by Average Equity for the period. Average Equity is calculated as average of the total equity at the beginning and ending of the period. RoAE is an indicator of our Company's efficiency as it measures our Company's profitability. RoAE is indicative of the profit generation by our Company against the equity contribution.
Return on Capital Employed ("RoCE"):	RoCE is calculated as Earnings before interest and taxes (EBIT) divided by Capital Employed by the Company for the period. RoCE is an indicator of our Company's efficiency as it measures our Company's profitability. RoCE is indicative of the profit generation by our Company against the capital employed.

Set forth the description of historic use of the KPIs by our Company to analyse, track or monitor the operational and/or financial performance of our Company.

For evaluation our business, we consider that the KPIs, as presented above, as additional measures to review and assess our financial and operating performance. These KPIs have limitations as analytical tools and presentation of these KPIs should not be considered in isolation or as a substitute for the Restated Consolidated Financial Information. Further, these KPIs may differ from the similar information used by other companies, including peer companies, and hence their comparability may be limited. Although these KPIs are not a measure of performance calculated in accordance with applicable accounting standards, our Company's management believes that it provides an additional tool for investors to use our operating results and trends and in comparing our financial results with other companies in our industry as it provides consistency and comparability with past financial performance.

7. Comparison of Key Performance Indicators with Listed Industry Peers

Particulars	<div> <div>(₹ in Thousands, other than the % and the ratios mentioned below)</div> </div>			
	Maitreya Medicare Ltd.	KMC Specialty Hospitals (India) Limited	Shalby Limited	Global Health Limited
		Financial Year ended March 31, 2023		
Revenue from Operations	393799.63	15,57564	80,49210	2,69,42483
EBITDA ⁽¹⁾	77323.27	4,13149	13,67430	61,22096
EBITDA Margin (%) ⁽²⁾	19.63%	26.53%	16.99%	22.72%
Restated profit for the period/year	42264	2,66884	6,76770	32,60793
Restated profit for the period/year Margin (%) ⁽³⁾	10.73%	17.13%	8.41%	12.10%
Return on Average Equity ("RoAE") (%) ⁽⁴⁾	15.83%	26.65%	7.50%	16.13%
Return on Capital Employed("RoCE")(⁽⁵⁾)	42.71%	23.29%	10.40%	9.57%

For further details, please see the chapter titled "BASIS FOR ISSUE PRICE" beginning on page 108 of the RHP.

ISSUE PROGRAMME

BID/ ISSUE OPENS ON: OCTOBER 27, 2023 | BID/ ISSUE CLOSES ON: NOVEMBER 01, 2023

** The company may, in consultation with the Book Running Lead Manager, consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Issue Period shall be one Working Day prior to the Bid/ Issue opening Date.*

THE EQUITY SHARES OF OUR COMPANY WILL GET LISTED ON SME PLATFORM OF NATIONAL STOCK EXCHANGE OF INDIA LIMITED ("NSE EMERGE")

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after such revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and Sponsor Bank.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(i) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50 % of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs", the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. (the "**Net QIB Portion**"). Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders ("**Non-Institutional Portion**") and not less than 35% of the Net Issue shall be available for allocation to Retail Individual Bidders ("**Retail Portion**") in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("**ASBA**") process providing details of their respective ASBA accounts, and UPI ID in case of RBIs using the UPI Mechanism. If applicable, in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("**SCSBs**") or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the Issue through the ASBA process. For details, see "Issue Procedure" beginning on page 315 of the Red Herring Prospectus. A copy of the Prospectus will be delivered for registration to the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

Bidders/Applicants should note that on the basis of PAN, DP ID and Client ID as provided in the Bid cum Application Form, the Bidders/Applicants may be deemed to have authorized the Depositories to provide to the Registrar to the Issue, any requested Demographic Details of the Bidders/ Applicants as available on the records of the depositories. These Demographic Details may be used, among other things, for or unblocking of ASBA Account or for other correspondence(s) related to an issue. Bidders/ Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Applicants' sole risk. Bidders/ Applicants should ensure that PAN, DP ID and the Client ID are correctly filled in the Bid cum Application Form. The PAN, DP ID and Client ID provided in the Bid cum Application Form should match with the PAN, DP ID and Client ID available in the Depository database, otherwise, the Bid cum Application Form is liable to be rejected. Bidders/Applicants should ensure that the beneficiary account provided in the Bid cum Application Form is active. Investors must ensure that their PAN is linked with AADHAR and are in compliance with CBDT Notification dated February 13, 2020 and press release dated June 25, 2021.

CONTENTS OF THE MEMORANDUM OF ASSOCIATION OF THE COMPANY AS REGARDS ITS OBJECTS: For information on the main objects and other objects of our Company, see section titled "History and Certain Corporate Matters" on page 166 of the Red Herring Prospectus and Clause III of the Memorandum of Association of our Company. The Memorandum of Association of our Company is a material document for inspection in relation to the Issue. For further details, see the section titled "*Material Contracts and Documents for Inspection*" on page 393 of the Red Herring Prospectus.

LIABILITY OF MEMBERS AS PER MOA: The liability of the members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.

<div> <div>ASBA *</div> <div>Simple, Safe, Smart way of Application-Make use of it!!!</div> </div> <div> <div>*Application Supported by Blocked Amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account. For further details check section on ASBA.</div> <div> <div>Mandatory in Public Issues.</div> <div>No cheque will be accepted.</div> </div> </div>	<div> </div> <div>UPI-Now available in ASBA for all individual investors applying in public issues where the application amount is up to ₹ 500,000, applying through Registered Brokers, Syndicate, CDPs & RTAs. UPI Bidders also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account. Investors are required to ensure that the bank account used for bidding is linked to their PAN. Bidders must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and the subsequent press releases, including press release dated June 25, 2021 read with press release dated September 17, 2021.</div> <div> <div>ASBA has to be availed by all the investors except Anchor Investors. UPI may be availed by (i) Retail Individual Bidders in the Retail Portion; (ii) Non-Institutional Bidders with an application size of up to ₹ 5,00,000 in the Non-Institutional Portion and the (iii) Eligible Employees, under the Employee Reservation Portion. For details on the ASBA and UPI process, please refer to the details given in the Bid Cum Application Form and abridged prospectus and also please refer to the section "Issue Procedure" on page 315 of the RHP. The process is also available on the website of Association of Investment Bankers of India ("AIBI") and Stock Exchanges and in the General Information Document. The Bid Cum Application Form and the Abridged Prospectus can be downloaded from the website National Stock Exchange of India Limited ("NSE") and "Stock Exchange") and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpFees&intId=35 and http://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpFees&intId=43, respectively as updated from time to time. For the list of UPI apps and banks live on IPO, please refer to the link: www.sebi.gov.in. UPI Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appear on the website of SEBI, as updated from time to time. HDFC Bank Limited has been appointed as the Sponsor Banks for the Issue, in accordance with the requirements of SEBI circular dated November 1, 2018 as amended. For UPI related queries, investors can contact NPCI at the toll-free number-18001201740 and Mail ID- ipo.upi@npci.org.in. For issue related grievance investors may contact: GYR Capital Advisors Private Limited - Mr. Mohit Baid (+91 8777564648) (Email ID: info@gyrcapitaladvisors.com).</div> </div>	<div> <div>BOOK RUNNING LEAD MANAGER</div> <div> <div>GYR Capital Advisors</div> <div>GYR Capital Advisors Private Limited</div> <div>428, Gala Empire, Near JB Tower, Drive in Road, Thaltej, Ahmedabad-380 054, Gujarat, India.</div> <div>Telephone: +91 8777564648; E-mail id: info@gyrcapitaladvisors.com</div> <div>Website: www.gyrcapitaladvisors.com; Investor Grievance e-mail id: investors@gyrcapitaladvisors.com</div> <div>Contact Person: Mohit Baid; SEBIRegistrationNumber: INM000012810</div> <div>CIN: U67200GJ2017PT0396908</div> </div> </div>	<div> <div>REGISTRAR TO THE ISSUE</div> <div> <div>LINKIntime</div> <div>Link Intime India Private Limited</div> <div>C-101, 1st Floor, 247 Park, Lal Bhadur Shastri Marg, Vikhroli (West), Mumbai 400 043 Maharashtra, India</div> <div>Telephone: +91 810 811 4949; E-mail id: maitreyamedicare ipo@linkintime.co.in</div> <div>Website: www.linkintime.co.in; Investor Grievance e-mail id: maitreyamedicare ipo@linkintime.co.in</div> <div>Contact Person: Shanti Gopalkrishnan; SEBI Registration Number: INR000004058</div> <div>CIN No: U67190MH1999PT118368</div> </div> </div>	<div> <div>COMPANY SECRETARY AND COMPLIANCE OFFICER</div> <div> <div>Ms Payal Mathur</div> <div>Maitreya Medicare Limited</div> <div>Nr. Someshwara Char Rasta, U.M Road, Surat City, Surat, Gujarat-395007 India.</div> <div>Telephone No.: +91 98798 89506; E-mail: cs@maitreyamedicareld.com; Website: www.maitreyahospitals.com</div> </div> </div>

AVAILABILITY OF RED HERRING PROSPECTUS: Investors should note that Investment in Equity Shares involves a degree of risk and are advised to refer to the Red Herring Prospectus and the Risk Factors contained therein before applying in the Issue. Full copy of the Red Herring Prospectus is available on the website of the company at www.maitreyahospitals.com, the website of the BRLM to the Issue at www.gyrcapitaladvisors.com and the website of NSE India at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#fsmse_offer and is available on the websites of the BRLMs at www.gyrcapitaladvisors.com.

AVAILABILITY OF BID-CUM-APPLICATION FORMS: Bid-Cum-Application forms can be obtained from the Registered Office of the Company: **MAITREYA MEDICARE LIMITED**, Tel: +91 98798 89506, Registered office of the BRLM: GYR Capital Advisors Private Limited, and at the selected locations of the Self Certified Syndicate Banks; Registered Brokers; Designated RTA Locations and Designated CDPs participating in the Issue. Bid-cum-application Forms will also be available on the websites of NSE Emerge and the designated branches of SCSBs, the list of which is available at websites of the stock exchanges and SEBI.

BANK(S) TO THE ISSUE/ REFUND BANK/ SPONSOR BANK: HDFC BANK LIMITED

LINK TO DOWNLOAD ABRIDGED PROSPECTUS: www.gyrcapitaladvisors.com

UPI: Retail Individual Bidders can also Bid through UPI Mechanism

All capitalised terms used herein and not specifically defined shall have the same meaning as ascribed to them in the Red Herring Prospectus

Place: Surat, Gujarat
Date: October 20, 2023

Disclaimer: MAITREYA MEDICARE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares the Red Herring Prospectus dated October 19, 2023 has been filed with the Registrar of Companies, Gujarat and thereafter with SEBI and the Stock Exchanges. The RHP is available on the website of NSE Emerge at https://www.nseindia.com/companies-listing/corporate-filings-offer-documents#fsmse_offer and is available on the websites of the BRLMs at www.gyrcapitaladvisors.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, please refer to the Red Herring Prospectus including the section titled "Risk Factors" beginning on page 32 of the Red Herring Prospectus.

The Equity Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "**Securities Act**") or any United States securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities laws. The Equity Shares are being issued and sold outside the United States in offshore transactions in reliance on Regulation "S" under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

ઓર્થોડોક્સ સેન્ટ પોર્ટીરિયસ ચર્